Flamel CEO Soula estimates that today 80% of FLML's revenue is from Micropump, while 80% of its expenses are from Medusa. "For Medusa, it will be two to three years before we have the same level ...

In real life, Flamel was a French scholar and bookseller who lived in the 14th and early 15th centuries. As great as it would be if "Harry Potter" was real, J.K. Rowling made sure the series was ...

There are a few "Harry Potter" cameos in "Fantastic Beasts: The Crimes of Grindelwald" and one of them feels incredibly wasted.

Mr, Flamel, who celebrated his six hundred and sixty-fifth birthday last year, enjoys a quiet life in Devon with his wife, Perenelle (six hundred and fifty-eight)." ...

Nicolas Flamel's Story in the Books Despite his importance in the wizarding world, Flamel never actually appeared in the Harry Potter books. However, his back-story is revealed in Harry Potter and ...

LYON, FRANCE--(Marketwired - Dec 19, 2014) - Flamel Technologies (NASDAQ: FLML) today announced that its second clinical study in healthy volunteers using its proprietary Micropump ® technology ...

The nanotech firm faces a fiery shareholder fight. Everything about this company may be small -- its size, its business, its profits -- but it's got a big fight on its hands, and the drama is set ...

LYON, France--(BUSINESS WIRE)-- Flamel Technologies (Nasdaq:FLML) today announced its financial results for the second quarter of 2011. Highlights during the second quarter included:Two agreements ...

Flamel Technologies (NASDAQ: FLML) today announced the acquisition of FSC Holdings, LLC, together with its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC ...

Flamel.ai, a Covington-based AI-generated content design studio, announced a $2 million pre-seed round Monday. The raise follows the company's launch last fall. A new artificial intelligence ...

Flamel Technologies announced an agreement to license its Micropump technology -- a controlled release technology for the oral administration of small molecule drugs -- to GlaxoSmithKline , which ...